Kelun Group
Kelun Group, officially known as Kelun Pharmaceutical Co., Ltd., is a prominent player in the pharmaceutical industry, headquartered in China (CN). Founded in 2004, the company has rapidly expanded its operations across major regions, including Asia, Europe, and North America, establishing a strong global presence. Specialising in the research, development, and manufacturing of high-quality generic and innovative drugs, Kelun Group is recognised for its commitment to advanced biopharmaceuticals and injectable products. The company’s unique approach to drug formulation and production has positioned it as a leader in the market, with notable achievements in regulatory compliance and product quality. With a focus on enhancing healthcare solutions, Kelun Group continues to make significant strides in the pharmaceutical sector, contributing to improved patient outcomes worldwide.
DitchCarbon Score
How does Kelun Group's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kelun Group's score of 15 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Kelun Group's reported carbon emissions
In 2023, Kelun Group reported total carbon emissions of approximately 2,659,459,920 kg CO2e. This figure includes about 2,190,590,170 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and approximately 468,869,750 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Additionally, the company disclosed Scope 3 emissions, which totalled about 2,659,459,920 kg CO2e, encompassing all other indirect emissions that occur in the value chain. In 2022, Kelun Group's total emissions were approximately 2,372,000,000 kg CO2e, with Scope 1 emissions at about 2,136,000,000 kg CO2e and Scope 2 emissions at approximately 236,000,000 kg CO2e. This indicates a significant increase in emissions from 2022 to 2023. Despite the lack of specific reduction targets or initiatives disclosed, Kelun Group's emissions data highlights the importance of addressing their carbon footprint, particularly in light of the growing emphasis on sustainability and climate commitments within the pharmaceutical industry. The company has not yet established formal science-based targets or climate pledges, which are critical for aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 2,136,000,000 | 0,000,000,000 |
| Scope 2 | 236,000,000 | 000,000,000 |
| Scope 3 | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kelun Group is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
